Apatorsen clinical trials
Also written OGX-427.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses apatorsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 7
SCRI Development Innovations, LLC (2) · Achieve Life Sciences (2) · Noah Hahn, M.D. (1) · British Columbia Cancer Agency (1) · Costantine Albany (1) · Queen Mary University of London (1) · Vancouver Coastal Health (1)
Studies
Open first, then newest update. How each study uses apatorsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder CancerCompletedPhase 2Noah Hahn, M.D.NCT01780545Written as OGX-427
- OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving AbirateroneTerminatedPhase 2Costantine AlbanyNCT01681433Written as OGX-427
- OGX-427 in Castration Resistant Prostate Cancer PatientsCompletedPhase 2British Columbia Cancer AgencyNCT01120470Written as OGX-427
- Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung CancerCompletedPhase 2SCRI Development Innovations, LLCNCT01829113Written as OGX-427
- Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung CancersStatus unknownPhase 2Queen Mary University of LondonNCT02423590Written as Apatorsen (OGX-427)
- Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic CancerCompletedPhase 2SCRI Development Innovations, LLCNCT01844817Written as OGX-427
- A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder CancerCompletedPhase 2Achieve Life SciencesNCT01454089Written as OGX-427 600 mg
- Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder CancerCompletedPhase 1Achieve Life SciencesNCT00487786Written as OGX-427
- A Study for Treatment of Superficial Bladder Cancer Using OGX-427Status unknownPhase 1Vancouver Coastal HealthNCT00959868Written as OGX-427
Codes
What other systems call apatorsen · ClinicalTrials.gg INT000168
- MeSH (NLM) C000595177apatorsenOne source NLM
- UNII (FDA) IFJ6X26JW6APATORSENConfirmed FDA, NLM
- NCI Thesaurus C71740ApatorsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000595177 | apatorsen | One source NLM |
| UNII (FDA) | IFJ6X26JW6 | APATORSEN | Confirmed FDA, NLM |
| NCI Thesaurus | C71740 | Apatorsen | One source FDA |
Also registered as apatorsen sodium (UNII 3N4G7RE66Y).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.